<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8">
<title>“独角兽”药明康德回A，将迎千亿市值与国际巨头双重挑战</title>
</head>
<body>
<p><a href="https://mp.weixin.qq.com/s?timestamp=1524395841&amp;src=3&amp;ver=1&amp;signature=fRuSu3jxZXkDwKE8pKrHFzl8qoaGA98JC4RVJSXA*FKpzMctK5p3TIlqcExNQy1wHruCi7USLqr89FzBdLTFIFBGNWknNb-Wixd5eQwZ7SE*NK7o-*QUgicUxybra6k2KYp2-pRntUNr9sd43FWJ295HNWdzSkVtR7M8sjrS2Es=">原文</a></p>
<div id="img-content">
                
                <h2 class="rich_media_title" id="activity-name">
                    “独角兽”药明康德回A，将迎千亿市值与国际巨头双重挑战                                    </h2>
                <div id="meta_content" class="rich_media_meta_list">
                                        <span id="copyright_logo" class="rich_media_meta meta_original_tag">原创</span>
                                                            <em id="post-date" class="rich_media_meta rich_media_meta_text">2018-04-17</em>

                                        <em class="rich_media_meta rich_media_meta_text">李超</em>
                                        <a class="rich_media_meta rich_media_meta_link rich_media_meta_nickname" href="##" id="post-user">棱镜</a>
                    <span class="rich_media_meta rich_media_meta_text rich_media_meta_nickname">棱镜</span>


                    <div id="js_profile_qrcode" class="profile_container" style="display:none;">
                        <div class="profile_inner">
                            <strong class="profile_nickname">棱镜</strong>
                            <img class="profile_avatar" id="js_profile_qrcode_img" src="" alt="">

                            <p class="profile_meta">
                            <label class="profile_meta_label">微信号</label>
                            <span class="profile_meta_value">lengjing_qqfinance</span>
                            </p>

                            <p class="profile_meta">
                            <label class="profile_meta_label">功能介绍</label>
                            <span class="profile_meta_value">《正片》栏目，聚焦商业特写故事；《棱镜》栏目，聚焦泛财经深度调查。</span>
                            </p>
                            
                        </div>
                        <span class="profile_arrow_wrp" id="js_profile_arrow_wrp">
                            <i class="profile_arrow arrow_out"></i>
                            <i class="profile_arrow arrow_in"></i>
                        </span>
                    </div>
                </div>
                                
                
                
                
                                                
                                                                
                
                <div class="rich_media_content " id="js_content">
                    

                    

                    
                    
                    <p><br></p><section style="max-width: 100%;box-sizing: border-box;background-color: rgb(255, 255, 255);word-wrap: break-word !important;"><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-bottom: 10px;max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-top: -0.46em;margin-bottom: 0.1em;max-width: 100%;box-sizing: border-box;border-top: 2px solid rgb(160, 160, 160);border-bottom: 2px solid rgb(160, 160, 160);word-wrap: break-word !important;"><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;text-align: center;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;text-align: left;color: rgb(160, 160, 160);font-size: 14px;word-wrap: break-word !important;"><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">点击上方“棱镜”关注我们！带您解密财经，透视真相。</p></section></section></section></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;text-align: center;font-size: 15px;color: rgb(17, 9, 81);word-wrap: break-word !important;"><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><strong style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;">腾讯《一线》作者 李超</strong></p></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-left: auto;max-width: 100%;box-sizing: border-box;width: 2.5em;word-wrap: break-word !important;"><img class="" data-ratio="1" src="https://mmbiz.qpic.cn/mmbiz_png/ibjRVHevbSthfAy8MU5R6xmCsyIlpYIAz2EED1xjLMMrStL9cCdibIHHdNOKeELtYqhqrvF7LNZYqibaOSuPrtmfA/640?wx_fmt=png" data-type="png" data-w="144" style="box-sizing: border-box;width: 40px;word-wrap: break-word !important;visibility: visible !important;" width="100%"></section><section class="" style="margin-top: -0.8em;margin-bottom: 0.8em;padding-right: 2.5em;max-width: 100%;box-sizing: border-box;width: 670px;word-wrap: break-word !important;"><section style="max-width: 100%;box-sizing: border-box;width: 630px;height: 5px;background-image: -webkit-linear-gradient(left, rgb(128, 128, 128), rgba(255, 247, 234, 0));background-position: initial;background-size: initial;background-repeat: initial;background-attachment: initial;background-origin: initial;background-clip: initial;word-wrap: break-word !important;"></section></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="padding-right: 14px;padding-left: 14px;max-width: 100%;box-sizing: border-box;color: rgba(0, 0, 0, 0.580392);line-height: 1.8;letter-spacing: 1px;word-wrap: break-word !important;"><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">药明康德（603259.SH）4月16日发布的招股意向书显示，公司已经顺利拿到IPO批文，预计在A股发行时间为4月24日，预计发行价格为21.6元/股，申购代码732259。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">从事药品研发的药明康德，在去年7月14日首次发布IPO预披露材料，今年2月6日更新材料后，于3月27日IPO申请过会，加之本次顺利拿到批文并最终确定发行时间，也让其成为“独角兽”概念产生后第一个落地回归国内资本市场的行业龙头。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">尽管与之前IPO拟募集资金57亿元相比，其最新募集资金已缩水为21亿元，但相较2015年拆分前从美股私有化的32亿美元市值，拆分后独立回归A股的药明康德仍然身价倍增，尚未经历A股市场“洗礼”市值已经超过200亿元。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">最新的招股意向书表示，药明康德募集的21亿元资金将拟用于苏州药物安全评价中心扩建、天津化学研发实验室扩建升级、总部基地及分析诊断服务研发中心和补充流动资金四个项目。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><strong style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 21px;color: rgb(66, 63, 63);word-wrap: break-word !important;">CRO业务国内一枝独秀</span></strong></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">药明康德主要从事小分子药物（化学药）CRO和CMO/CDMO业务，即在药物发现及前期研发、临床前药学实验、工艺合成、临床试验等阶段，为制药企业提供研发、实验、生产等配套服务。其中，药明康德又主要从事临床前阶段的CRO业务，可以理解为为药企提供临床前研发外包服务。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">在药明康德计划回归A股的同时，国内同时有包括康龙化成（A17120.SZ）、美迪西（A17206.SZ）、睿智化学等多家同行业公司计划进入资本市场，药明康德无疑是其中翘楚。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">首先是体量上。披露信息显示，药明康德2015年到2017年营业收入分别为48.83亿元、61.16亿元和77.65亿元，净利润分别达到3.49万元、9.75亿元和12.27亿元，市场占有率国内排名第一位，全球排名第十一位。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">国内其他几家同样在去年7月左右申报上市但杳无音讯的CRO企业则相形见绌：康龙化成2015年到2017年的营收分别只有11.28亿元、16.34亿元和22.94亿元，美迪西2015年和2016年营收只有1.64亿元和2.32亿元，睿智化学同期营收则只有7.71亿元和8.64亿元。他们的营收总和还不及药明康德的一半。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">其次，药明康德的盈利能力也明显高于国内其他企业。2015年到2017年，其毛利率分别高达35%、41%和42%，净利率分别达到了14%、18%和17%，而同期康龙化成的毛利率则只有28%、29%和33%，净利率不到10%；2015年和2016年，美迪西的毛利率也只有36%。药明康德高出同行业5%-10%的毛利率水平，是国内药物CRO名副其实的“龙头”和“独角兽”企业。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><strong style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 21px;color: rgb(66, 63, 63);word-wrap: break-word !important;">分拆回归市值已破千亿</span></strong></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">2007年，药明康德在美国上市，彼时，上市主体拥有大分子药物（生物医）、小分子药物和医疗健康科技服务三块业务。2015年，药明康德以32.2亿美元私有化，同时主攻小分子药物，并独立出三家公司“东归”。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">其中，药明生物（02269.HK）主要承担大分子药物业务，在2017年6月登陆港股，2016年和2017年，药明生物营业收入分别为人民币9.89亿元和16.18亿元，净利润分别为1.41亿元和2.53亿元，股价从2016年的25港元/股左右上升到2018年的85港元/股左右，目前药明生物最新市值达到了900亿港元。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">另一家分拆出来的公司合全药业（832159）则在2015年4月登陆新三板，主要从事小分子药物的工艺研发、改进与生产服务。2015年到2017年，其营业收入分别达到了12.69亿元、16.38亿元和21.87亿元，净利润也分别达到了3.3亿元、4.36亿元和4.95亿元。相比新三板大量“僵尸”公司，合全药业成交活跃，其最新市值也达到了200亿元。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">药明康德32亿美元退市后，仅分拆出来的药明生物和合全药业两家企业，3年时间市值已经达到了1000亿元人民币，而一分为三中规模最大的药明康德的回归，让市场对其登陆A股后的市值充满了想象空间。对比药明生物和合全药业的盈利规模和估值水平，甚至有极端投资者认为，药明康德在A股上市后，市值有望单独突破1000亿。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><strong style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 21px;color: rgb(66, 63, 63);word-wrap: break-word !important;">能否挑战国际巨头？</span></strong></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">药明康德招股意向书显示，目前全球已有超过50%的药企选择聘用专业CRO企业协助新药研发服务，以降低自身研发费用并控制风险。根据统计数据，2012年至2016年，全球CRO行业的销售额由231亿美元上升至326亿美元，年复合增长率达到8.78%。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">尽管行业保持增速，药明康德也已坐稳国内龙头，但其同样面临巨大挑战。药明康德的客户主要来自于国际大型制药公司，在国际市场上，行业龙头为美国昆泰公司（quintiles）公司，2016年昆泰与另一巨头IMS合并，当年合并后的Quintiles-IMS营收达到了68亿美元，业务范围遍布全世界100多个国家。此外，美国的LabCorp、Parexel、PPD和Inc Research等公司也在药明康德之前，营收基本也在20亿美元左右，业绩和规模均远超药明康德。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">招股意向书中也表示，全球制药研发服务市场竞争日趋激烈，药明康德在特定的服务领域面临的竞争对手既包括各类专业CRO/CMO/CDMO机构，也包括大型药企自身的研发部门，其中多数为国际化大型药企或研发机构，这些企业或机构相比药明康德具备更强的财力、技术能力、客户覆盖度。除了上述成熟的竞争对手以外，药明康德还面临来自市场新入者的竞争，他们或拥有更雄厚的资金实力，或拥有更有效的商业渠道，或在细分领域拥有更强的研究实力。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">可以说，药明康德在坐稳国内“老大”后，将在国际市场面临更为残酷的厮杀。不知回归A股后，在国内资本市场的“呵护”和资金加持下，药明康德是否能在国际巨头面前站稳脚跟并更进一步。</p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;"><br style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"></p></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;text-align: right;font-size: 14px;color: rgb(160, 160, 160);word-wrap: break-word !important;"><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;word-wrap: break-word !important;">运营编辑：范晟男</p></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-top: 0.5em;margin-bottom: 0.5em;max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;word-wrap: break-word !important;overflow: hidden !important;"><img class="__bg_gif" data-ratio="0.1125" src="https://mmbiz.qpic.cn/mmbiz_gif/ibjRVHevbSthfAy8MU5R6xmCsyIlpYIAzvfGXEgQdqHUicExrGvCMrvvYmUyiat7kXTozZ5tR15aia9h5QiaGbHEic7w/640?wx_fmt=gif" data-type="gif" data-w="640" style="box-sizing: border-box;background-color: rgb(238, 237, 235);border-width: 1px;border-style: solid;border-color: rgb(238, 237, 235);background-size: 22px;background-position: center center;background-repeat: no-repeat;vertical-align: middle;height: 72px !important;word-wrap: break-word !important;width: 640px !important;"></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-top: 10px;margin-bottom: 10px;max-width: 100%;box-sizing: border-box;text-align: center;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;word-wrap: break-word !important;overflow: hidden !important;"><img class="" data-ratio="0.6875" src="https://mmbiz.qpic.cn/mmbiz_jpg/ibjRVHevbSthfAy8MU5R6xmCsyIlpYIAzNibNdJTJicjePe4ecUt7uaiczdIXqx2icJicibnOiaicZibWA7AHG3lkfMwXQicA/640?wx_fmt=jpeg" data-type="jpeg" data-w="640" style="box-sizing: border-box;vertical-align: middle;word-wrap: break-word !important;width: auto !important;visibility: visible !important;"></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="margin-top: 0.5em;margin-bottom: 0.5em;max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;background-color: rgb(160, 160, 160);height: 1px;word-wrap: break-word !important;"></section></section></section><section class="" powered-by="xiumi.us" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><section class="" style="max-width: 100%;box-sizing: border-box;word-wrap: break-word !important;"><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;text-align: center;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(160, 160, 160);word-wrap: break-word !important;"></span><span style="max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(160, 160, 160);word-wrap: break-word !important;">【一线】为腾讯旗下产品，第一时间为你提供独家、一手的商业资讯。</span><span style="max-width: 100%;box-sizing: border-box;color: rgb(160, 160, 160);font-size: 14px;letter-spacing: 0px;word-wrap: break-word !important;"></span></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;text-align: center;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(160, 160, 160);word-wrap: break-word !important;"> </span></p><p style="max-width: 100%;box-sizing: border-box;min-height: 1em;text-align: center;word-wrap: break-word !important;"><span style="max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(160, 160, 160);word-wrap: break-word !important;">合作or新闻线索提供，联系邮箱:lengjingtxcj@qq.com</span></p></section></section></section></section>
                </div>
                <script nonce="315217109" type="text/javascript">
                    var first_sceen__time = (+new Date());

                    if ("" == 1 && document.getElementById('js_content')) {
                        document.getElementById('js_content').addEventListener("selectstart",function(e){ e.preventDefault(); });
                    }

                    
                    (function(){
                        if (navigator.userAgent.indexOf("WindowsWechat") != -1){
                            var link = document.createElement('link');
                            var head = document.getElementsByTagName('head')[0];
                            link.rel = 'stylesheet';
                            link.type = 'text/css';
                            link.href = "//res.wx.qq.com/mmbizwap/zh_CN/htmledition/style/page/appmsg/page_mp_article_improve_winwx3d171e.css";
                            head.appendChild(link);
                        }
                    })();
                </script>
                
                
                                
                <div class="ct_mpda_wrp" id="js_sponsor_ad_area" style="display:none;"></div>

                
                                <div class="reward_area tc" id="js_preview_reward" style="display:none;">
                    <p id="js_preview_reward_wording" class="tips_global reward_tips" style="display:none;"></p>
                    <p>
                        <a class="reward_access" id="js_preview_reward_link" href="##"><span class="icon-reward"></span>赞赏</a>

                    </p>
                </div>
                <div class="reward_qrcode_area reward_area tc" id="js_preview_reward_qrcode" style="display:none;">
                    <p class="tips_global">长按二维码向我转账</p>
                    <p id="js_preview_reward_ios_wording" class="reward_tips" style="display:none;"></p>
                    <span class="reward_qrcode_img_wrp"><img class="reward_qrcode_img" src="//res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/pic/appmsg/pic_reward_qrcode.2x3534dd.png"></span>
                    <p class="tips_global">受苹果公司新规定影响，微信 iOS 版的赞赏功能被关闭，可通过二维码转账支持公众号。</p>
                </div>
                            </div><div class="rich_media_tool" id="js_toobar3">
                
                                
                                            <div id="js_read_area3" class="media_tool_meta tips_global meta_primary" style="display:none;">阅读 <span id="readNum3"></span></div>

                <span style="display:none;" class="media_tool_meta meta_primary tips_global meta_praise" id="like3">
                    <i class="icon_praise_gray"></i><span class="praise_num" id="likeNum3"></span>
                </span>

                <a id="js_report_article3" style="display:none;" class="media_tool_meta tips_global meta_extra" href="##">投诉</a>

            </div><div class="rich_media_tool" id="js_sg_bar">
                
                                
                                
            </div>
<script async defer="defer" src="https://www.googletagmanager.com/gtag/js?id=UA-7909075-5"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){ dataLayer.push(arguments); }
gtag('js', new Date());
gtag('config', 'UA-7909075-5');
</script>
</body>
</html>
